{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:23:07Z","timestamp":1792570987351,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.esmoop.2026.107695","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:31:26Z","timestamp":1778761886000},"page":"107695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5255-6620","authenticated-orcid":false,"given":"R.","family":"S\u00e1nchez-Bayona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Nicol\u00e1s-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-5065","authenticated-orcid":false,"given":"C.","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8755-8626","authenticated-orcid":false,"given":"J.M.","family":"Cejalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Llabr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-5877","authenticated-orcid":false,"given":"A.","family":"Falc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1485-5080","authenticated-orcid":false,"given":"S.","family":"Pernas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0742-1150","authenticated-orcid":false,"given":"A.","family":"L\u00f3pez de Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-5727","authenticated-orcid":false,"given":"M.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hinojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-9554","authenticated-orcid":false,"given":"T.","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2105-1213","authenticated-orcid":false,"given":"B.","family":"Cantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1566-9586","authenticated-orcid":false,"given":"M.J.","family":"Echarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gallegos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-1030","authenticated-orcid":false,"given":"C.","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7816-7589","authenticated-orcid":false,"given":"S.","family":"Escriv\u00e1-de-Roman\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3556-6947","authenticated-orcid":false,"given":"B.","family":"Fullana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4821-4081","authenticated-orcid":false,"given":"M.A.","family":"Cobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6626-4434","authenticated-orcid":false,"given":"A.","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Joval-Ramentol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-3183","authenticated-orcid":false,"given":"T.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8934-6627","authenticated-orcid":false,"given":"C.","family":"Valdivia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2796-1042","authenticated-orcid":false,"given":"E.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rodriguez-Antona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.esmoop.2026.107695_bib1","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/14737140.2022.2147510","article-title":"The evolving therapeutic landscape of antibody-drug conjugates in breast cancer","volume":"22","author":"Chen","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.esmoop.2026.107695_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.breast.2022.10.016","article-title":"Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer","volume":"66","author":"Rassy","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.esmoop.2026.107695_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102922","article-title":"Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?","volume":"135","author":"G\u00e9raud","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107695_bib4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2217\/pgs.14.29","article-title":"Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers","volume":"15","author":"Wang","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107695_bib5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/pharmaceutics17050542","article-title":"Dose-limiting toxicities and the maximum tolerated dose of irinotecan based on UGT1A1 genotypes: a systematic review","volume":"17","author":"D\u00edaz-Villamar\u00edn","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107695_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt.70060","article-title":"UGT1A1 and sacituzumab govitecan toxicity: a systematic review and meta-analysis","volume":"119","author":"Dello Russo","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107695_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107695_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.gene.2014.09.009","article-title":"UGT1A1 sequence variants associated with risk of adult hyperbilirubinemia: a quantitative analysis","volume":"552","author":"Chen","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.esmoop.2026.107695_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104265","article-title":"UGT1A1 testing in breast cancer: should it become routine practice in patients treated with antibody-drug conjugates?","volume":"196","author":"Ibrahim","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107695_bib10","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cpt.2096","article-title":"Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors","volume":"109","author":"Yin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2026.107695_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107695_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107695_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/COC.0000000000001126","article-title":"Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: an updated systematic review and meta-analysis of clinical trials","volume":"47","author":"Qureshi","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107695_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104787","article-title":"Adverse effect of trastuzumab deruxtecan in solid tumours: a systematic review and meta-analysis","volume":"213","author":"Pathak","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107695_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107695_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107695_bib17","first-page":"1","article-title":"MICE: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.esmoop.2026.107695_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2021.12.009","article-title":"UGT1A1 genotype-guided dosing of irinotecan: a prospective safety and cost analysis in poor metaboliser patients","volume":"162","author":"Hulshof","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.107695_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2020.09.007","article-title":"Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: ready for prime time","volume":"141","author":"Hulshof","year":"2020","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107695_bib21","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cpt.2291","article-title":"Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan","volume":"110","author":"Yin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.esmoop.2026.107695_bib22","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1080\/00498254.2018.1531158","article-title":"Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys","volume":"49","author":"Nagai","year":"2019","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107695_bib23","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.esmoop.2026.107695_bib24","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-21-0397","article-title":"Visualization of intratumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis","volume":"27","author":"Suzuki","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.esmoop.2026.107695_bib25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","article-title":"A common MUC5B promoter polymorphism and pulmonary fibrosis","volume":"364","author":"Seibold","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107695_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12881-020-01005-1","article-title":"Association between FCGR2A rs1801274 and MUC5B rs35705950 variations and pneumonia susceptibility","volume":"21","author":"Shi","year":"2020","journal-title":"BMC Med Genet"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107695_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223371","article-title":"Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease","volume":"14","author":"Udagawa","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2026.107695_bib28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pharmtox-052120-014115","article-title":"HLA allele-restricted immune-mediated adverse drug reactions: framework for genetic prediction","volume":"62","author":"Jaruthamsophon","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107695_bib29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.annonc.2024.04.002","article-title":"Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation","volume":"35","author":"Peters","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107695_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10191","key":"10.1016\/j.esmoop.2026.107695_bib31","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.esmoop.2026.107695_bib32","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.20.03398","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:12:51Z","timestamp":1780290771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926016376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2059702926016376"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107695","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107695"}}